MicroQuin Secures DoD CDMRP Grant for Innovative Lung Cancer Treatment Development

Lung cancer remains one of the deadliest cancers worldwide, with survival rates still lagging despite advances in medicine. MicroQuin, a biotechnology company focused on developing new therapies, has recently received a significant grant from the Department of Defense’s Congressionally Directed Medical Research Programs (DoD CDMRP). This funding will support MicroQuin’s efforts to develop a promising new treatment for lung cancer, aiming to improve outcomes for patients facing this challenging disease.

MicroQuin laboratory equipment for lung cancer treatment development